The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Hengrui Medicine
Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
 
Binghe Xu
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche
Research Funding - Jiangsu Hengrui Medicine (Inst)
 
Qingyuan Zhang
No Relationships to Disclose
 
Pin Zhang
No Relationships to Disclose
 
Xichun Hu
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Hengrui Pharmaceutical; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Novartis
 
Wei Li
No Relationships to Disclose
 
Zhongsheng Tong
Research Funding - Bio-Thera; Company; Hengrui Medicine; Lilly; Novartis
 
Tao Sun
No Relationships to Disclose
 
Yuee Teng
No Relationships to Disclose
 
Xinhong Wu
No Relationships to Disclose
 
Quchang Ouyang
No Relationships to Disclose
 
Xi Yan
Research Funding - Hengrui Medicine
 
Jing Cheng
No Relationships to Disclose
 
Qiang Liu
No Relationships to Disclose
 
Jifeng Feng
No Relationships to Disclose
 
Xiaojia Wang
Research Funding - Hengrui Medicine; Pfizer; Roche
 
Xiaoyu Zhu
Employment - Jiangsu Hengrui Medicine
 
Fei Wu
Employment - Hengrui Medicine
 
Xiao Zhang
Employment - Hengrui Medicine
 
Jianjun Zou
No Relationships to Disclose